B&L and Alcon settle dispute amicably

Article

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

Bausch & Lomb claimed that Alcon's promotional use of a chart to demonstrate the safety of contact lens solutions could negatively influence patients and/or doctors. The chart shows the safety of different solutions based on corneal staining tests, rating them with a colour coding system: green is safe, yellow means use with caution and red indicates the solution is unsafe. Bausch & Lomb alleged that the chart was produced without scientific studies or clinical evidence to back it up.

Alcon has agreed to change the red/yellow colour scheme and in light of this the lawsuit has been dismissed.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Hattie Hayes
March 13th 2025
Article

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Left to Right – Back Row: Peter Holland, CEO, IAPB, H.E. Gladys Mokhawa, Permanent Representative of Botswana to the United Nations, H.E Ambassador Walton Webson, Permanent Representative of Antigua and Barbuda to the United Nations &             Co-Chair and Founder of the UN Friends of Vision Group, Dr. A.H. Monjurul Kabir, Global Adviser and Team Leader, Gender Equality and Disability Inclusion, Mr. Werner Obermeyer, Director WHO, New York Front Row: Jennifer Gersbeck, Executive Director – Influence and Scaling Impact at The Fred Hollows Foundation and Co-Chair of the IAPB Gender Equity Work Group, HRH The Duchess of Edinburgh, Ms Tara Soomro, Permanent Mission of United Kingdom to the United Nations & Ambassador ECOSOC Affairs . Image courtesy of the International Agency for the Prevention of Blindness.

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

Hattie Hayes
March 12th 2025
Article

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

Advanced therapies in neovascular AMD and DMO: Experts weigh in

Hattie Hayes
March 12th 2025
Article

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

A black-and-white image of a woman placing her hand over her eye, as if in pain. A red glow on her eye area indicates she is experiencing neuropathic corneal pain. Image credit: ©mykolasamoilenk – stock.adobe.com

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

Martin David Harp
March 11th 2025
Article

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

A close-up of an eyeball looking at the tip of a syringe needle. There is a droplet of liquid coming from the syringe. Concept image for anti-VEGF and diabetic macular oedema. Image credit: ©kikkerdirk – stock.adobe.com

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Lynda Charters
March 11th 2025
Article

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

© 2025 MJH Life Sciences

All rights reserved.